Targeting RUNX/Core Binding Factor-dependency in relapsed and poor prognosis acute lymphoblastic leukaemiaProfessor Tariq Enver, UCL Cancer Institute
Establish a comprehensive surveillance system for adverse health outcomes in British survivors of childhood, teenage and young adult cancerProf. Mike Hawkins, University of Birmingham
Aneuploidy is a driver of childhood cancer and a target for novel therapies.Professor Christine Harrison, Professor Jonathan Higgins and Professor Steve Clifford, Newcastle University
Improving immunotherapies for the treatment of leukaemiaDr Anindita Roy and Professor Anastasios Karadimitris, University of Oxford and Imperial College London
Understanding why some children inherit a greater risk of developing cancerProfessor Richard Houlston, The Institute of Cancer Research
Improving outcomes for children whose leukaemia relapses after treatmentDr David O’Connor, Professor Marc Mansour and Dr Jack Bartram, University College London Cancer Institute and Great Ormond Street Institute of Child Health
One of the greatest medical success stories of the last century is the amazing growth in the survival from childhood cancer. Fifty years ago, only a quarter of children diagnosed with cancer survived. Today, more than 80 per cent of young patients can be successfully treated.
However, cancer still claims the lives of around 250 children every year in the UK. And unfortunately the children who survive may be left with serious health and developmental problems as a result of the intensive treatments used to save their young lives.
Through our investment in research, we are taking forward our understanding of childhood cancer, to give new insights into ways of treating young patients with even the most difficult forms of cancer. We hope to drive up the survival rate still further whilst reducing the risk of harm.